Telomir Pharmaceuticals, Inc. Common Stock (NASDAQ:TELO) — Stock Price
Telomir Pharmaceuticals, Inc. Common Stock (NASDAQ:TELO) is currently trading at $1.17 USD, up 0.86% today. Over the past 52 weeks, shares have ranged between $0.92 and $1.93. This page tracks Telomir Pharmaceuticals, Inc. Common Stock's live share price on the NASDAQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Telomir Pharmaceuticals, Inc. Common Sto (TELO) total market value.
Telomir Pharmaceuticals, Inc. Common Stock (TELO) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Telomir Pharmaceuticals, Inc. Common Stock's daily closing share price and trading volume on the NASDAQ exchange over the past year, giving a clear view of recent price momentum and liquidity.
Telomir Pharmaceuticals, Inc. Common Stock Income Statement — Revenue, Profit & Earnings by Year
Telomir Pharmaceuticals, Inc. Common Stock's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | — | — | $3.94 Million | — | — |
| Gross Profit | — | — | $-3.94 Million | — | — |
| Research & Development | $2.44 Million | $2.24 Million | $1.57 Million | $833.21K | $126.49K |
| SG&A | $8.10 Million | $9.64 Million | $600.19K | $20.94K | $11.64K |
| Total Operating Expenses | $10.54 Million | $12.24 Million | $3.94 Million | $854.15K | $138.13K |
| Operating Income | $-10.54 Million | $-12.24 Million | $-3.94 Million | $-854.15K | $-138.13K |
| EBITDA | $-10.41 Million | $48.00K | $-11.43 Million | $-854.15K | $-138.13K |
| EBIT | — | $-12.19 Million | $-3.94 Million | $-1.71 Million | $-276.26K |
| Interest Expense | $0.00 | $4.34 Million | $1.64 Million | $0.00 | — |
| Income Before Tax | $-10.41 Million | $-16.53 Million | $-13.07 Million | $-854.15K | $-138.13K |
| Income Tax Expense | — | $-16.53 Million | $-2.30 Million | $-854.14K | $-138.13K |
| Net Income | $-10.41 Million | $-16.53 Million | $-13.07 Million | $-854.15K | $-138.13K |
Telomir Pharmaceuticals, Inc. Common Stock Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Telomir Pharmaceuticals, Inc. Common Stock's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | $7.34 Million | $1.32 Million | $4.77 Million | $48.73K | $55.00K |
| Total Current Assets | $7.34 Million | $1.32 Million | $435.23K | $48.73K | $0.00 |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | — | — | — | — |
| Net Receivables | — | — | $130.00K | — | — |
| Inventory | — | — | $303.28K | — | — |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | — | — | — | — | — |
| Total Liabilities | $1.43 Million | $680.97K | $1.34 Million | $986.01K | $138.13K |
| Total Current Liabilities | $1.43 Million | $680.97K | $1.34 Million | $986.01K | $138.13K |
| Long-term Debt | — | — | — | — | — |
| Net Debt | $-7.29 Million | $-1.17 Million | $99.77K | $580.37K | $119.40K |
| Total Stockholder Equity | $5.91 Million | $643.04K | $3.44 Million | $-937.28K | $-83.13K |
| Retained Earnings | $-41.01 Million | $-30.60 Million | $-14.06 Million | $-992.28K | $-138.13K |
Telomir Pharmaceuticals, Inc. Common Stock Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Telomir Pharmaceuticals, Inc. Common Stock generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | $-3.69 Million | $-5.07 Million | $-3.86 Million | $-468.66K | $-119.40K |
| Capital Expenditures | $0.00 | $0.00 | $4.00 | $0.00 | $4.00 |
| Free Cash Flow | $-3.69 Million | $-5.07 Million | $-3.86 Million | $-468.66K | $-119.40K |
| Investing Cash Flow | — | — | — | — | — |
| Financing Cash Flow | $9.71 Million | $6.34 Million | $3.86 Million | $470.08K | $119.40K |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | $5.29 Million | $6.87 Million | $0.00 | — | — |
| Depreciation | — | $4.34 Million | $1.61 Million | — | — |
| Change in Cash | $6.02 Million | $1.26 Million | $-188.00 | $1.42K | $0.00 |
Telomir Pharmaceuticals, Inc. Common Stock Earnings History — EPS Actual vs. Analyst Estimates
Track Telomir Pharmaceuticals, Inc. Common Stock's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Aug 13, 2026 | — | — | — |
| May 12, 2026 | -0.03 | — | — |
| Feb 25, 2026 | -0.06 | — | — |
| Nov 10, 2025 | -0.03 | -0.07 | +57.14% |
| Aug 14, 2025 | -0.17 | -0.08 | -112.50% |
| May 14, 2025 | -0.07 | -0.10 | +30.00% |
| Feb 04, 2025 | -0.10 | -0.05 | -100.00% |
| Nov 11, 2024 | -0.20 | — | — |